BioLife Solutions, a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, has received the Interphex 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.
Frozen CellSeal CryoCase is a rigid cryogenic containment system designed to protect biologic materials during freezing, storage, and distribution.
CellSeal CryoCase was developed in response to documented container failures in CGT manufacturing, where flexible cryobags have historically been susceptible to stress fractures and seal fatigue from cycles of controlled rate freezing, liquid nitrogen storage, and distribution. CryoCase provides reinforced structural protection across the full frozen product journey while remaining compatible with closed system manufacturing workflows.
As CGT programmes scale toward commercialisation, regulators are paying closer attention to how frozen products are handled and inspected. CryoCase supports visual inspection for container integrity and potential particulates while giving manufacturers greater confidence in containment across product development.
Launched in 2025, CryoCase is available as part of BioLife’s CellSeal portfolio.
